Masterclass: Pear Therapeutics: What Happened and What does this mean for DTx?

Earlier this year, the digital health industry was rocked by the news that Pear Therapeutics had become insolvent and was looking for a lifeline, which never materialised. An undisputed trailblazer in prescription digital therapeutics (PDTs), Pear achieved many firsts for PDTs throughout its journey, won several battles, but eventually lost the war.

We’re all left asking: What happened? Does it spell doom for the industry? What can we learn from this story? Can we pick up where they left off? And more importantly… Should we pick up where they left off?

Join Eugene Borukhovich (YourCoach Health), Eriola Kruja and Ryan Rossier (ZS), in this interactive masterclass, to discuss the key achievements and challenges that defined the Pear Therapeutic story, including the following contributing factors:

1. The innovator tax
2. The commercialisation headwind
3. The double adoption barrier
4. The value quotient
5. The capital context